Frances Anastassacos
@fran_anastas
Followers
405
Following
9K
Media
3
Statuses
138
Excited to share @nablabio is partnering with 3 of the world’s largest pharma cos to use integrated AI and wet-lab tech to design antibodies against challenging disease targets. Thrilled to also add @radicalvcfund who led our $26M Series A to the family!
12
40
117
RT @SurgeBiswas: Tech report of our de novo antibody design platform, JAM, is now up on biorxiv! We added new results showing JAM-generated….
0
59
0
RT @nablabio: Our own Adithya Paramasivam will be giving a talk on our work in de novo antibody design at the BioLogic Summit in San Diego….
0
3
0
RT @SurgeBiswas: If you're at BioLogic in San Diego next week, check out Adithya's talk on our work in de novo antibody design! https://t.c….
0
5
0
RT @LifeSciVC: The bigger question for me is whether VC money is the rate-limiting factor today for innovation. I don't think it is: 10x….
0
25
0
RT @owl_posting: Better antibodies by engineering targets, not engineering antibodies (Nabla Bio). another startup….
0
26
0
RT @endpts: Tiny startup Nabla Bio posted a preprint Thursday highlighting its progress in creating antibodies from scratch that look thera….
0
10
0
RT @sethbannon: The @nablabio team has been quietly building the future of AI x Bio. Today they shared incredible de novo antibody design c….
0
8
0
RT @MartinPacesa: Really nice complementary work to our computational solubilisation of GPCRs and Claudins! Glad our approach is inspiring….
0
10
0
RT @dreidco: Amazing work from @SurgeBiswas and the team at @NablaBio — the era of de novo drug design is HERE.
0
3
0
RT @SurgeBiswas: We designed de novo VHH (nanobodies) to SARS-CoV-2 RBD. We saw a 0.6% success rate, and top designs had double-digit nM af….
0
1
0
RT @SurgeBiswas: Lastly, we used JAM to successfully generate antibodies against two difficult, insoluble, multipass membrane protein targe….
0
1
0
RT @SurgeBiswas: Incredibly excited to share new results from Nabla Bio where we show we can design antibodies de novo for use in therapeut….
0
62
0
RT @AndrewE_Dunn: “My hat is off to them for choosing targets well and not settling for a bunch of academic papers that settle five-decade-….
0
17
0
RT @ceeceeboom: Boom Capital is hiring a Chief of Staff. 🚀 This is one of our most important hires. You'll liaise with our in-house scienti….
0
28
0
RT @prateekvjoshi: The topic on Infinite ML pod today is -- Designing antibodies with AI. We have @SurgeBiswas on the show to talk about i….
0
3
0
RT @SurgeBiswas: Seth Ela + 50Y were the first to believe in us and wrote us a 700k check in 2020 to get us started. That was first life fo….
0
8
0
Reminder to check out @SurgeBiswas’s talk @PEGSboston later today!.
I’m speaking today at @PEGSboston, 5:10 pm, Eng Antibodies. Talk will cover new “solMPMP” tech from @nablabio where we use generative ML to create soluble proxies of valuable multipass membrane protein drug targets, and use these proxies to facilitate design of new biologics.
0
2
8
RT @nablabio: Today we announce the close of a $26M Series A financing, led by @radicalvcfund with participation from all existing investor….
0
11
0
Thanks to @ZettaVentures @khoslaventures @fiftyyears @cantos @ycombinator @ceeceeboom for doubling down this round and continuing to believe in the mission! Onwards / back to work.
1
0
12
Revenue and insights from these collaborations are helping us grow more sustainably and build focused technology to solve real problems in drug design.
1
0
3